News
-
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
LIR Life Sciences Corp. enters into a services agreement with Oxygen Handel GmbH to initiate Phase 0 strategic development planning for transdermal metabolic therapeutics pipeline -
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
LIR Life Sciences Corp. announces successful completion of comparative mouse study evaluating skin-permeation delivery of GLP/GIP-based therapies. Results presented at ENDO 2026 -
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Neuland Laboratories Limited orders raw materials for Phase 1 of macromolecule-enabled transdermal delivery development with LIR Life Sciences Corp. to advance needle-free, skin-applied peptide therapies -